Fecal Microbiota Transplant for Irritable Bowel Syndrome: Panacea or Placebo?

Aasma Shaukat, Darren M. Brenner

Research output: Contribution to journalEditorialpeer-review

3 Scopus citations

Abstract

Irritable bowel syndrome (IBS) is a common disorder of heterogeneous pathogenesis, and alterations in the gut microbiome/dysbiosis play a role in the development of symptoms in a subset of individuals with IBS. Consequently, it stands to reason that modulation of the microbiome via fecal microbial transplant (FMT) may serve as an effective treatment strategy because this has proven effective for treating other illnesses such as Clostridium difficile colitis. Small studies completed to date have offered conflicting results and the strains used, route of administration, and IBS subtypes may all play a role in treatment outcomes. A better understanding of the altered microbiome of patients with IBS and more rigorous trials are warranted before the utility of fecal microbial transplant for IBS symptoms can be determined.

Original languageEnglish (US)
Pages (from-to)1032-1033
Number of pages2
JournalThe American journal of gastroenterology
Volume114
Issue number7
DOIs
StatePublished - Jul 1 2019

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Fecal Microbiota Transplant for Irritable Bowel Syndrome: Panacea or Placebo?'. Together they form a unique fingerprint.

Cite this